gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · COLLHealthcarePharmaceuticals

Collegium Pharmaceutical, Inc. Common Stock (COLL)

$23.67−0.25%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$23.73▼ 34.27% in range
Nov 3, 2025Low $21.53 · High $49.84Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Collegium Pharmaceutical closed at $23.67 on Nov 4, down 0.25%, 52.5% below its 52-week closing high. Volume of 804.6K shares was 1.30× its 20-day average (above normal).

Split-adjusted performance: +8.2% over one month, -35.2% over six months, -34.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $199.88M, up 6.3% from a year earlier, with a net margin of -7.5%.

Short interest was 5.4M shares at the Oct 15 settlement, down 2.6% from the prior report (17.6% of float, 7.2 days to cover).

Market cap$770.6M32.6M shares
Revenue · quarter$199.9M+6.3% YoY
Diluted EPS$-0.46−235.3% YoY
P/E · TTM16.1×P/S 1.0×
Net margin-7.5%Gross 86.7%
Dividend yieldNone
52-week range21.53 – 49.84−52.5% from high
Volume804.6K1.30× 20-day avg
Volatility · 60d33.9%Annualised
Short % of float17.6%7.2 days to cover
Net cash-$962.1MCash $129.5M
Next earnings—Not scheduled
Split-adjusted performance
1W +1.9%1M +8.2%3M −18.7%6M −35.2%YTD −48.9%1Y −34.4%3Y +9.0%5Y +14.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum37
Revenue growth51
Net margin64
Value (low P/E)50
Size67

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short5.4M−2.6% vs prior
Days to cover7.2Settled Oct 15
% of float17.6%
Short vol. 10d54.8%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
COLLCollegium Pharmaceutical$23.67−0.25%−35.2%+6.3%−7.5%16.1$770.6M
ABUSArbutus Biopharma$4.06+4.64%−8.1%−90.6%−512.0%5.3$804.3MCompare
ANNXAnnexon$4.33+3.34%−24.0%———$820.9MCompare
WVEWave Life Sciences$3.62+1.12%−50.3%+72.9%−470.5%—$714.0MCompare
SGMTSagimet Biosciences Inc. Series A$9.99+0.40%+19.2%———$708.4MCompare
AKTSAktis Oncology$15.20+1.74%−24.1%—−713.5%—$845.4MCompare
CYRXCryoPort$16.70+1.52%+31.6%+7.7%−20.9%—$845.8MCompare
ALMSAlumis$6.55+0.77%−74.3%−37.7%−8557.2%—$847.8MCompare
ARDXArdelyx$3.29+8.58%−53.7%+15.7%−0.6%—$849.4MCompare

News about Collegium Pharmaceutical

All news →
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across MassachusettsGlobeNewswire Inc. · 6d ago▲ PositiveCollegium to Report Third Quarter 2026 Financial Results on November 5, 2026GlobeNewswire Inc. · Oct 22, 2026NeutralCOLL vs. DSNKY: Which Stock Is the Better Value Option?Zacks Investment Research · Oct 19, 2026▲ PositiveDoes Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?Zacks Investment Research · Oct 16, 2026▲ PositiveCollegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · Jun 5, 2026Neutral

Quick answers

What does Collegium Pharmaceutical do?
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain.
What is COLL's market cap?
$770.59M, based on the Nov 4 close of $23.67.
What is COLL's P/E ratio?
16.1× trailing-twelve-month earnings of $47.91M.
Does Collegium Pharmaceutical pay a dividend?
No regular cash dividend has been paid in the last year.
How much of COLL is sold short?
5.4M shares, 17.6% of float, as of Oct 15, 2026.
What sector is COLL in?
Healthcare, in the Pharmaceuticals industry.

About Collegium Pharmaceutical

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

HQ: Stoughton, MA423 employeesListed May 7, 2015collegiumpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology